Vertex Pharmaceuticals: Label Expansions For ALYFTREK And TRIKAFTA Plus Strong Demand

Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ALYFTREK and TRIKAFTA. Read the latest analysis on the stock here.
Morningstar

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States -With this expansion, any ...

Vertex Pharmaceuticals (VRTX) Valuation Check After FDA Expands ALYFTREK And TRIKAFTA Use

Vertex Pharmaceuticals (VRTX) is back in focus after the U.S. Food and Drug Administration expanded use of its cystic ...
Business Insider

Vertex' Trikafta Gets Expanded FDA Approval For Cystic Fibrosis Treatment

(RTTNews) - Vertex Pharmaceuticals (VRTX) said Friday the U.S. Food and Drug Administration expanded its approval of a cystic fibrosis treatment, encompassing more patients with different types of ...
Business Wire

Vertex Presents New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA ®

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...
Barchart on MSN

What to expect from Vertex Pharmaceuticals’ Q1 2026 earnings report

With a market cap of $112.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies, best known for its leading ...
Seeking Alpha

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the ...
Times Argus

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK ® (vanzacaftor ...